^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Nasopharyngeal Carcinoma
    Drug:capecitabine (Thymidylate synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    12/21/2020
    Excerpt:
    Nasopharyngeal carcinoma: Recommendations...management of advanced/metastatic disease...active agents include paclitaxel, docetaxel, 5-FU, capecitabine, irinotecan, vinorelbine, ifosfamide, doxorubicin, oxaliplatin and cetuximab, which can be used as single agents or in selected combinations.
    DOI:
    10.1016/j.annonc.2020.12.007
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Nasopharyngeal cancer: Recurrent/Unresectable or Metastatic (with no surgery or RT option)…Other Recommended Regimens (First-Line)…Single Agents…Capecitabine
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet
    Title:

    Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial

    Published date:
    06/07/2021
    Excerpt:
    Failure-free survival at 3 years was significantly higher in the metronomic capecitabine group (85·3% [95% CI 80·4–90·6])...The addition of metronomic adjuvant capecitabine to chemoradiotherapy significantly improved failure-free survival in patients with high-risk locoregionally advanced nasopharyngeal carcinoma, with a manageable safety profile.
    DOI:
    https://doi.org/10.1016/S0140-6736(21)01123-5
    Trial ID:
    NCT02958111